Hypercholesterolemia
Conditions
Brief summary
The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Ecklonia cava extract on hyperlipidemia.
Detailed description
The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Ecklonia cava extract on hyperlipidemia. The investigators measured improvement of lipid profile, including total cholesterol, triglyceride, HDL-cholesterol, and LDL-cholesterol.
Interventions
DIETARY_SUPPLEMENTECE (Ecklonia cava extract)
ECE 200mg, twice a day
DIETARY_SUPPLEMENTPlacebo
Placebo 200mg, twice a day
Sponsors
Chonbuk National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Mild hypercholesterolemic subjects(≥200mg/dL of total cholesterol or ≥110mg/dL of LDL-cholesterol)
Exclusion criteria
* Self-reported pregnancy, lactation * Prevalent heart disease, cancer, renal disorder, or diabetes mellitus, and use of lipid-lowering drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in total cholesterol | 12 weeks |
| Changes in LDL-cholesterol | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Changes in triglyceride | 12 weeks |
| Changes in HDL-cholesterol | 12 weeks |
| Changes in waist to hip ratio | 12 weeks |
Countries
South Korea
Outcome results
None listed